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PVIEWPOINT
Taking Cardiovascular Genetic
Association Studies to the Next Level
Geoffrey S. Ginsburg, MD, PHD,*† Svati H. Shah, MD, MHS,† Jeanette J. McCarthy, PHD*‡
Durham, North Carolina
Genetic information is beginning to have a direct impact on patient care and it is important that cardiologists
appreciate the value and approaches to associating genetic variation and health outcomes. Genetic associations
should be based on compelling genetic and biological hypotheses and should be statistically sound so as to re-
duce the possibility of “false discovery” in the setting of testing multiple hypotheses. Study designs should
clearly define cases and controls and measurement of phenotypes. Finally, findings should be replicated in at
least 1 independent cohort. Consideration of these principles should provide insight into disease biology based
on genetic findings and encourage their meaningful adoption into clinical practice. (J Am Coll Cardiol 2007;50:
930–2) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.025c
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aardiovascular medicine is undergoing a paradigm shift
rom acute intervention to predictive and preventive care.
he latter approach has been afforded largely through the
vailability of the human genome sequence and technologies
hat allow us to access its vast and complex information
ontent. The enthusiasm for these new approaches, partic-
larly genetic association studies, to predicting acute coro-
ary syndromes, myocardial infarction, sudden death from
rrhythmias, and response to commonly used cardiovascular
edications needs to be tempered by a critical evaluation of
ata supporting their clinical validity. To this end, we
elieve that it is important for every cardiologist to appre-
iate the value and approaches to associating genetic varia-
ion and outcomes such that the true meaning of these
ndings can be readily assimilated into the mainstream of
ardiovascular patient care.
It has been over 10 years since the Journal of the American
ollege of Cardiology (JACC) published its first genetic
ssociation studies. At that time there was a flurry of papers
n the angiotensin-converting enzyme gene insertion/
eletion polymorphism and its association with idiopathic
ardiomyopathy, myocardial infarction, left ventricular hy-
ertrophy, or the lack of these (1–4). A prescient accom-
anying editorial stated, “The increasingly widespread avail-
bility and easy applicability of molecular genetic tools
rovides the research community with a formidable oppor-
unity to, at long last, begin uncovering the heritable
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ommunity and Family Medicine, Duke University Medical Center, Durham, North
arolina.p
Manuscript received April 20, 2007; revised manuscript received May 11, 2007,
ccepted May 23, 2007.omponent of complex diseases. In many cases . . . these
ools may not be applied with the stringency that an
pidemiologic geneticist may deem appropriate. However,
s long as we view the data with critical reservation . . .
issemination of such studies is vital to stimulate the field,
o usher in new developments, and to generate new hypoth-
ses that eventually will be tested in more robust study
esigns” (5). Many journals, including JACC, continue to
trive toward these goals of dissemination of innovation,
articularly in genetics and genomics. However, in the case
f genetic studies, in our opinion, it is now time to raise the
ar and increase the stringency for publication, particularly
n terms of study design.
The last decade has seen seminal milestones in genetics:
he complete sequencing of the human genome, the com-
letion of HapMap, the development and enhancement of
tatistical analysis tools, and the banking of deoxyribonu-
leic acid (DNA) from large populations. Today, with
enotyping a mere commodity and many clinical researchers
ollecting DNA routinely as part of longitudinal cross-
ectional studies and clinical trials, one can easily envision a
eluge of single gene/single nucleotide polymorphism
SNP) studies to generate new hypotheses of the type
nvisioned by Lindpaintner and Pfeffer (5). It is most
ertainly true that some reported “positive” associations are
he result of false discovery, and concomitantly there is a
egative publication bias that ensues because the vast
ajority of “negative” associations are not reported on at all.
The cardiovascular literature is now robust with positive
enetic association studies (6), but few have become clini-
ally meaningful. Many have failed to replicate outside the
riginal study, and for others replication has not been
ttempted. Many reasons exist for failure to replicate,
articularly for complex polygenic disorders, including in-
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ng variables, lack of sufficient power in replication cohorts,
nalyses in inappropriate subgroups, and genetic and phe-
otypic heterogeneity. Invaluable resources have gone into
rocuring DNA from patients, SNP detection, genotyping,
nalysis, and publication, the latter raising false hopes and
xpectation for a novel tool that will benefit patients and
ake physicians’ diagnostic and therapeutic acumen more
recise. Moreover, as a result of some of these errant studies,
he “hype” of genetics’ potential contribution to medicine
ow casts a shadow on its real opportunity to change the
eld. We believe that there is now a need for higher
tandards and greater uniformity in the design of studies in
ursuit of novel genetic susceptibility loci for cardiovascular
iseases and that, if they adopt these standards, studies will
e more likely to contribute to the field of cardiovascular
ealth care.
Both readers and authors of genetic association studies
hould look for certain features in the evaluation of these
tudies and in deciding whether the “take-home message” is
ne that is of potential clinical import.
ssociation studies should be based on a compelling
enetic hypothesis. If the study is not the first to examine
variant or set of variants at a particular locus, all the
revious genetic studies of this locus should be summarized
s they relate to the specific phenotype under study. If it is
he first study of a gene, supporting biological data that
akes the gene a good candidate should be outlined. Good
andidate genes will have multiple lines of evidence to
upport a possible role in disease, including, but not limited
o, expression in the appropriate tissue, differential expres-
ion in experimental models of disease/normal tissue, phe-
otypes of transgenic or knockout animals, and so forth, or
location consistent with previous linkage or whole-
enome association study results. Although the gene is not
equired to be a positional candidate, the chromosomal
ocation of the gene and whether it is consistent with
inkage or whole-genome association hits should be pro-
ided. Even in whole-genome association studies that are
nherently unbiased, a biological hypothesis for selection of
he gene or genes further evaluated on the basis of the study
hould be clearly formulated.
ssociation studies should provide a clear rationale for
election of SNPs for study. With 1 SNP occurring in as
ew as every 185 bases and as many as 80 SNPs per gene, it
s no longer sufficient to genotype 1 or a few randomly
elected SNPs in a gene to draw any concrete conclusions.
he exception might be an SNP that has been clearly
emonstrated and accepted to be functional, i.e., whose
ranslation product results in a protein with altered function.
ut even then, we cannot ignore the possibility of allelic
eterogeneity at the locus, with different functional alleles
rising in distinct founder populations. Studies should aim
o unambiguously define the methods and process used for
electing one particular set of SNPs over another. Because
aplotypes reduce the need for defining individual SNPs, ldeally a comprehensive survey of
aplotype-tagged SNPs that
apture common variation and
unctional SNPs should be
ncluded.
If more than 1 SNP per gene
s examined, measures of linkage
isequilibrium (LD) between the
oci should be presented. If only
SNP is examined, it would be
seful to provide public HapMap data on LD in the region
f that variant, when it exists, with the goal of delineating
he boundaries of the association. This would allow readers
s well as the authors to define the relevant “blocks” of DNA
hat are being covered by the studied variants.
Details on allele frequency—particularly for the ethnic
roup(s) under investigation—as well as any information on
nown (or putative) functionality of SNPs should also be
ncluded to develop and allow readers to understand the
ationale for SNP selection.
ssociation studies should provide a solid biological
oundation for the findings. This notion directly stems
rom the preceding concept, that functional SNPs be given
significant weight in selection for study. When a genetic
nding is directly tied to the biology underlying the disease
f interest, more likely than not it will be clinically relevant
r lead to clinically relevant findings. Investigations should
trive to provide novel functional data pertaining to the gene
nd associated genes and pathways—or substantiation of
hese from the literature—and to provide a measure of the
ffect of the gene, genes, or pathway gene products in the
uman cohort(s) studied. These data will greatly strengthen
he plausibility of the association. For example, if the study
laims a positive association of a functional C-reactive
rotein (CRP) promoter polymorphism with myocardial
nfarction, the study should also investigate the effect of the
ariant on the intermediate phenotype of CRP levels.
here is a need to reduce the possibility of “false
iscovery” in the setting of testing multiple hypotheses.
n many studies, numerous variants, genetic models, and
henotypes are tested in the study population, and often
ithin substrata of the population. This multiple hypothesis
esting increases the opportunity for type I error. Appropri-
te statistical analyses to correct for multiple independent
omparisons (Bonferroni correction, Monte-Carlo simula-
ion, and permutation testing, false discovery rate) should be
erformed and the results discussed in this context. A
esign that contemplates validating the findings in a second
ata set is preferred to reduce the possibility of a false
ositive finding.
indings should be replicated in at least 1 independent
ohort. In the early days of genetic association studies,
erely finding an association was significant. Today, with
he deluge of associations published and the complexity of
he study design, populations, and phenotypes, this is no
Abbreviations
and Acronyms
CRP  C-reactive protein
DNA  deoxyribonucleic
acid
LD  linkage disequilibrium
SNP  single nucleotide
polymorphismonger sufficient. Clinical relevance of these findings will
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Cardiovascular Genetic Association Studies September 4, 2007:930–2nly be assured if they are robust to replication. This may be
ne of the most important aspects of genetic associations
nd establishing their relevance to medicine and broad
opulations. If the study is a replication study, then the
riginal study or studies that identified the candidates and
he populations in which the association was originally
escribed should be clearly described. Furthermore, there
hould be clear and careful delineation of the phenotype in
oth the initial and validation cohorts, with discussion
egarding potential dissimilarities (and, therefore, potential
onfounders). If it is an original study of a novel SNP, then
vidence of replication of the association in an independent
ohort should be provided. Thus true replication obviates
he need for power calculations, because the replication
hows that the study is sufficiently powered to detect the
ssociation.
hen are negative results important? We recognize the
egative publication bias incurred by not publishing studies
hat show a lack of association. There may be cases of
mport if such a study makes a significant contribution to
he scientific literature. In many cases, such studies might
nclude the testing of undisputable functional SNPs or
omprehensive genotyping (tagging) to exclude association
ith at least common variants of the gene. There also must
e a demonstration of adequate power to detect effect sizes
hat are below the original reported association, consistent
ith the lower confidence limit of the original effect
easured (7). It should also be recognized that it is very
ifficult to rule out an association with a gene owing to
omplexities of interaction, allelic heterogeneity, and the
ffect of rare variants that are not always captured.
tudy designs should be clear on the selection of cases
nd controls or cohorts, definition and measurement of
he phenotype, and acknowledgment of potential biases
nd confounding. What are the clinical characteristics or
henotype the study is aiming to associate with underlying
enetic variation? Phenotypic definition must be clear for
oth cases and controls and consistent with standards of
ractice or clinical guidelines where possible (8). For exam-
le, in association studies for coronary artery disease, dis-
inctions need to be made for myocardial infarction versus
ngiographic coronary disease phenotypes. If standards exist
hat define a phenotype, event, or outcome, then thesehould be used in the definition of the association under
tudy. Confounding by ethnicity, or population stratifica-
ion, is of particular concern in genetic association studies.
t a minimum, the potential for population stratification in
he study should be addressed and, ideally, methods should
e used to control for such confounding, such as conducting
amily-based studies or using genomic control or ancestry
nformative markers.
It is difficult to prescribe with exactitude the ideal genetic
tudy. The goal for both readers and writers of genetic
ssociation studies is to ensure that the evidence will
nstigate investigation into mechanism and biology based on
enetic findings and encourage the performance of studies
hat will enable the meaningful adoption of genetics into
linical practice.
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